{
    "eid": "2-s2.0-85120495726",
    "title": "Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer",
    "cover-date": "2021-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Medicine (all)",
            "@code": "2700",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Caroline Even",
        "Hung Ming Wang",
        "Shau Hsuan Li",
        "Roger K.C. Ngan",
        "Arunee Dechaphunkul",
        "Li Zhang",
        "Chia Jui Yen",
        "Po Chung Chan",
        "Somvilai Chakrabandhu",
        "Brigette B.Y. Ma",
        "Suebpong Tanasanvimon",
        "Victor H.F. Lee",
        "Pei Jen Lou",
        "Zujun Li",
        "Alexander I. Spira",
        "Ammar Sukari",
        "Jo\u20acel Guigay",
        "Steven McCune",
        "Juan Gonzalez-Maffe",
        "Sebastian Szpakowski",
        "Yao Yao",
        "Hongzi Liang",
        "Jennifer Mataraza",
        "Romain Sechaud",
        "Luigi Manenti",
        "Darren W.T. Lim"
    ],
    "citedby-count": 23,
    "ref-count": 41,
    "ref-list": [
        "Nasopharyngeal carcinoma- review of the molecular mechanisms of tumorigenesis",
        "The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging",
        "Nasopharyngeal cancer: an update on diagnosis and treatment",
        "Evaluation of 7th edition of AJCC staging system for nasopharyngeal carcinoma",
        "State-of-the-art management of nasopharyngeal carcinoma: current and future directions",
        "Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099",
        "Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety",
        "Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma",
        "Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results",
        "Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma",
        "Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge",
        "Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial",
        "Combination of gemcitabine and carboplatin chemotherapy for recurrent nasopharyngeal carcinoma",
        "Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy",
        "A first-inhuman phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors",
        "Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742)",
        "Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study",
        "Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials",
        "Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type",
        "Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy",
        "Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma",
        "Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy",
        "A phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nanopharyngeal carcinoma",
        "A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy",
        "IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade",
        "BRAF-mutant transcriptional subtypes predict outcome of combined BRAF, MEK, and EGFR Blockade with dabrafenib, trametinib, and panitumumab in patients with colorectal cancer",
        "STAR: ultrafast universal RNA-seq aligner",
        "HTSeq-a Python framework to work with highthroughput sequencing data",
        "edgeR: a Bioconductor package for differential expression analysis of digital gene expression data",
        "NCBI viral genomes resource",
        "Immuno-oncology trial endpoints: capturing clinically meaningful activity",
        "KEYNOTE-122: phase 2 study of pembrolizumab versus standard-of-care chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma",
        "An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC)",
        "Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase ii clinical trial (POLARIS-02)",
        "Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma",
        "EBV-driven LMP1 and IFN-g up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy",
        "Programmed cell death 1 (PD-1) ligand (PD-L1) expression in solid tumors as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors: a systematic review and meta-analysis",
        "ASCO 2021. Oral presentation"
    ],
    "affiliation": [
        {
            "affiliation-city": "Basel",
            "@id": "60009968",
            "affilname": "Novartis International AG",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009968",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60031913",
            "affilname": "Chang Gung Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031913",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Guangzhou",
            "@id": "60082502",
            "affilname": "Sun Yat-Sen University Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60082502",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Tainan",
            "@id": "60073386",
            "affilname": "National Cheng Kung University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073386",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Taipei",
            "@id": "60073385",
            "affilname": "National Taiwan University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073385",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Detroit",
            "@id": "60033199",
            "affilname": "Barbara Ann Karmanos Cancer Institute",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60033199",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": null,
            "@id": "60033020",
            "affilname": "Queen Mary Hospital Hong Kong",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60033020",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "New York",
            "@id": "60032105",
            "affilname": "NYU Langone Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032105",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Singapore City",
            "@id": "60031809",
            "affilname": "National Cancer Centre, Singapore",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031809",
            "affiliation-country": "Singapore"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Villejuif",
            "@id": "60027386",
            "affilname": "Institut de Cancerologie Gustave Roussy",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60027386",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Nice",
            "@id": "60021628",
            "affilname": "Centre Antoine &#x96; Lacassagne",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021628",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Hong Kong",
            "@id": "60014234",
            "affilname": "Queen Elizabeth Hospital Hong Kong",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60014234",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60013855",
            "affilname": "Maharaj Nakorn Chiang Mai Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013855",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hatyai",
            "@id": "60006314",
            "affilname": "Prince of Songkla University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006314",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hong Kong",
            "@id": "60002798",
            "affilname": "Chinese University of Hong Kong",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002798",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Hong Kong",
            "@id": "60000139",
            "affilname": "Tuen Mun Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000139",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Marietta",
            "@id": "127329130",
            "affilname": "Medical Oncology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/127329130",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Fairfax",
            "@id": "125336008",
            "affilname": "Medical Oncology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/125336008",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Shanghai",
            "@id": "117724273",
            "affilname": "Novartis Institutes for BioMedical Research",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/117724273",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Cambridge",
            "@id": "110182158",
            "affilname": "Novartis Oncology Translational Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/110182158",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "Boehringer-Ingelheim",
        "Bristol Myers Squibb",
        "Eli Lilly",
        "Pfizer",
        "AstraZeneca",
        "Merck",
        "Novartis",
        "Roche",
        "Novartis Pharmaceuticals Corporation",
        "Merck Sharp & Dohme"
    ]
}